Mandate

Vinge advises Calliditas in connection with a directed share issue

The Board of Directors of Calliditas Therapeutics AB (publ) (“Calliditas”) has resolved on a directed new issue of shares, whereby the company will raise proceeds of approximately SEK 210 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Carnegie Investment Bank and Zonda Partners.

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts. 

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin and Edin Agic.

Related

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025

Vinge has advised Stirling Square Capital Partners (“SSCP”) in connection with the sale of part of its holding in Infobric to KKR

Pursuant to the transaction, KKR has become a significant owner, while SSCP will remain the largest owner.
October 15, 2025

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 1 billion

Vinge has advised ABG Sundal Collier in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 1 billion, and parallel written procedure to increase the bond framework to SEK 2 billion.
October 15, 2025